FDA Calls for Greater Compliance With FAR Reporting Requirements
This article was originally published in The Gold Sheet
FDA examines field alert report data for early warnings of emerging quality issues, but finds only questions as many companies submit few if any FARs to the agency. Meanwhile, some manufacturers are finding benefits from reporting and dealing with drug defects and errors, improving corporate culture and in one case saving nearly $1 billion.
You may also be interested in...
Infractions that have delayed Copaxone generic in plant Pfizer acquired when it bought Hospira suggest that pattern of quality issues may be continuing. Warning letter assigns eight tasks related to particulate contamination.
Customer complaints and internal quality systems activities drove brand/generic recalls last year while FDA was away inspecting compounding pharmacies.
Voluntary hold on Propofol, Liposyn will negatively impact 2010 sales, though acquisition of Orchid will help make up the difference.